Obesity Landscape - Final Thoughts Dosing The GLP-1 RA obesity market, driven by injectables, has seen historic levels of success, and near-term entrants are likely to provide more dosing options within the GLP-1 or GLP-1/GIP class Weight Loss Novel drugs in development are likely to be approved within the next 5 years, with improved weight loss efficacy compared to what Wegovy and Zepbound have demonstrated Body Comp The coming years will likely see increased data on muscle preservation and the quality of weight loss with novel MoAs, even if used in combination with GLP-1/incretin-targeting agents As the obesity market matures, how will patients think about the tradeoffs between efficacy, safety, and dosing/convenience with the availability of new drugs and more data
For information about supplements that have been investigated in humans for athletic performance and joint health, see our Reviews of Muscle and Workout Supplements , Collagen Supplements , Nitric Oxide Supplements , and Joint Health Supplements
According to Mayo Clinic, these drugs are among the most effective tools available today for managing both blood sugar and body weight in adults
Ozempic (semaglutide) Prescribing Information
FDA guidance for industry combined with initial FDA feedback specific to the pivotal Phase 3 program of avexitide for PBH suggest that reduction in hypoglycemia events could be an endpoint to support approval following positive results from a pivotal Phase 3 clinical trial
Weaning in rats: ii
